Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure

Cardiovascular Research

Volumn 63, Issue 2, 2004, Pages 236-244

  Hanna, Nessrine ^a   Cardin, Sophie ^a   Leung, Tack Ki ^b   Nattel, Stanley ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Angiotensin; Arrhythmias; Atrial fibrillation; Heart failure; Remodeling

Indexed keywords

ANGIOTENSIN; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL INFILTRATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART ATRIAL REMODELING; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HISTOPATHOLOGY; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TISSUE DISTRIBUTION; TISSUE LEVEL; TISSUE REPAIR; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARDIAC PACING, ARTIFICIAL; CELL DEATH; DOGS; FIBROSIS; HEART ATRIA; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; LEUKOCYTES; MITOGEN-ACTIVATED PROTEIN KINASES; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR REMODELING;

EID: 3142646893     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.03.026     Document Type: Article

References (37)

1. Jessup M., Brozena S. Heart failure. N. Engl. J. Med. 348:2003;2007-2018
2. Ehrlich J.R., Nattel S., Hohnloser S.H. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J. Cardiovasc. Electrophysiol. 13:2002;399-405
3. Goette A., Juenemann G., Peters B., et al. Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. Cardiovasc. Res. 54:2002;390-396
4. Li D., Fareh S., Leung T.K., et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 100:1999;87-95
5. Shinagawa K., Shi Y.-F., Tardif J.C., Leung T.-K., Nattel S. Dynamic nature of the atrial fibrillation substrate during the development and reversal of heart failure in dogs. Circulation. 105:2002;2672-2678
6. Cha T.J., Ehrlich J.R., Zhang L., et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation. 109:2004;412-418
7. Cardin S., Li D., Thorin-Trescases N., et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and independent pathways. Cardiovasc. Res. 60:2003;315-325
8. Cesselli D., Jakonuik I., Barlucchi L., et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog-dilated cardiomyopathy. Circ. Res. 89:2001;279-286
9. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing induced congestive heart failure. Circulation. 104:2001;2608-2614
10. Annes J.P., Munger J.S., Rifkin D.B. Making sense of latent TGFbeta activation. J. Cell Sci. 116:2003;217-224
11. Gaballa M.A., Goldman S. Ventricular remodeling in heart failure. J. Card. Fail. 8(Suppl. 6):2002;S476-S485
12. Aime-Sempe C., Folliguet T., Rucker-Martin C., et al. Myocardial cell death in fibrillating and dilated human right atria. J. Am. Coll. Cardiol. 34:1999;1577-1586
13. Goette A., Staack T., Rocken C., et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. Coll. Cardiol. 35:2000;1669-1677
14. Goette A., Arndt M., Rocken C., et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation. 101:2000;2678-2681
15. Goette A., Lendeckel U., Klein H.U. Calpains and cytokines in fibrillating human atria. Am. J. Physiol. (Heart Circ. Physiol.). 283:2002;H264-H272
16. Shi Y., Ducharme A., Li D., et al. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc. Res. 52:2001;217-225
17. Boixel C., Fontaine V., Rucker-Martin C., et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J. Am. Coll. Cardiol. 42:2003;336-344
18. Hoit B.D. Matrix metalloproteinases and atrial structural remodeling. J. Am. Coll. Cardiol. 42:2003;345-347
19. Hunt M.J., Aru G.M., Hayden M.R., et al. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am. J. Physiol. (Lung Cell. Mol. Physiol.). 283:2002;L239-L245
20. Arndt M., Lendeckel U., Röcken C., et al. Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria. Circulation. 105:2002;720-725
21. Force T., Michael A., Kilter H., Haq S. Stretch-activated pathways and left ventricular remodeling. J. Card. Fail. 8(6 Suppl.):2002;S351-S358
22. Ravingerova T., Barancik M., Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol. Cell. Biochem. 247:2003;127-138
23. Schulz R., Aker S., Belosjorow S., et al. Stress kinase phosphorylation is increased in pacing-induced heart failure in rabbits. Am. J. Physiol. (Heart Circ. Physiol.). 285:2003;H2084-H2090
24. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc. Res. 54:2002;347-360
25. Kumagai K., Nakashima H., Urata H., et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 41:2003;2197-2204
26. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 100:1999;376-380
27. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 107:2003;2926-2931
28. Roberts A.B., Sporn M.B., Assoian R.K., et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. U. S. A. 83:1986;4167-4171
29. Kupfahl C., Pink D., Friedrich K., et al. Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc. Res. 46:2000;463-475
30. el-Agroudy A.E., Hassan N.A., Foda M.A., et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am. J. Nephrol. 23:2003;300-306
31. Ma M., Watanabe K., Wahed M.I., et al. Inhibition of progression of heart failure and expression of TGF-beta 1 mRNA in rats with heart failure by the ACE inhibitor quinapril. J. Cardiovasc. Pharmacol. 38(Suppl. 1):2001;S51-S54
32. Lim D.S., Lutucuta S., Bachireddy P., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 103:2001;789-791
33. Hocher B., Godes M., Olivier J., et al. Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J. Hypertens. 20:2002;745-751
34. Nakajima H., Nakajima H.O., Salcher O., et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ. Res. 86:2000;571-579
35. Olgin J.E., Verheule S. Transgenic and knockout mouse models of atrial arrhythmias. Cardiovasc. Res. 54:2002;280-286
36. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 108:2003;3006-3010
37. Umana E., Solares C.A., Alpert M.A. Tachycardia-induced cardiomyopathy. Am. J. Med. 114:2003;51-55